SCOTUS Spin-Off: Novartis Seeks Preemption for Brand Drugmakers

The Novartis v. Fussman liability case pending before the Supreme Court should extend to prescription drugmakers similar preemptive protection from state court-ordered punitive damages as those now afforded generic drug companies, a brief filed by the Washington Legal Foundation argues.
Drug Industry Daily